Among all the new molecules under study at the moment, in our opinion, there are two drugs that more than any other are poised to become part of the future treatment algorithm for elderly and/or unfit CLL patients—the BTK inhibitors zanubrutinib and pirtobrutinib (formerly known as LOXO-305). Here, BTK is linked to B-cell chronic lymphocytic leukemia.